MarketCap
Facebook
X
Telegram
Intellia Therapeutics Income Statement 2025-2011 | NTLA
Brief overview of income trends at Intellia Therapeutics
The overview follows changes across a five-year period. Revenue at Intellia Therapeutics moved from 58 million dollars in 2020 to 67.7 million dollars in 2025. The five-year change reached +16.7%, while CAGR stood at 3.1%. Sales changed only slightly and remained broadly flat.
The five-year EBITDA result moved by −231%: from −130 million dollars to −431 million dollars. Operating performance weakened relative to revenue. The EBITDA share of revenue changed from −224.6% to −637.2%. The business retained less EBITDA from each unit of revenue.
Across the five years, the net result shifted from −$134 million to −$413 million. The loss widened and increased the financial risk.
Market capitalization changed from 3.5 billion dollars to 776 million dollars (−77.9%). Capitalization lags the underlying business improvement.
Overall conclusion
Signs of deterioration dominate the five-year picture. The overall view is constrained by lower investor confidence, a softer top-line trend and limited operating profitability. Future reports should be judged by revenue momentum, margins, and the conversion of sales into net income.
Annual Income Statement Intellia Therapeutics
| 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Market Cap |
776 M | 1.08 B | 2.43 B | 2.98 B | 6.7 B | 3.51 B | 563 M | 593 M | 935 M | 279 M | - | - | - | - | - |
Shares |
108 M | 98.8 M | 88.8 M | 77 M | 70.9 M | 56 M | 47.2 M | 43.1 M | 36 M | 22.2 M | - | - | - | - | - |
Historical Prices |
7.16 | 10.9 | 27.4 | 38.8 | 94.6 | 62.6 | 11.9 | 14.1 | 25.7 | 12.9 | - | - | - | - | - |
Net Income |
-413 M | -519 M | -481 M | -474 M | -268 M | -134 M | -474 M | -85.3 M | -67.5 M | -31.6 M | -12.4 M | - | - | - | - |
Revenue |
67.7 M | 57.9 M | 36.3 M | 52.1 M | 33.1 M | 58 M | 43.1 M | 30.4 M | 26.1 M | 16.5 M | 6.04 M | - | - | - | - |
Operating Income |
-441 M | -534 M | -515 M | -458 M | -268 M | -137 M | -106 M | -90.9 M | -69.6 M | -32.2 M | -13.4 M | - | - | - | - |
Interest Expense |
28.3 M | 15.2 M | 34.1 M | -16 M | -42 K | 2.35 M | 6.84 M | - | - | - | - | - | - | - | - |
EBITDA |
-431 M | -524 M | -506 M | -451 M | -261 M | -130 M | -101 M | -86.4 M | -66.6 M | -31.1 M | -13.1 M | - | - | - | - |
Operating Expenses |
- | - | - | - | - | - | - | 121 M | 95.7 M | 48.6 M | - | - | - | - | - |
General and Administrative Expenses |
120 M | 126 M | 116 M | 90.3 M | 71.1 M | 44.2 M | 41.1 M | 32.2 M | 28 M | 16.8 M | 8.28 M | - | - | - | - |
All numbers in USD currency
Quarterly Income Statement Intellia Therapeutics
| 2026-Q2 | 2026-Q1 | 2025-Q3 | 2025-Q2 | 2025-Q1 | 2024-Q4 | 2024-Q3 | 2024-Q2 | 2024-Q1 | 2023-Q4 | 2023-Q3 | 2023-Q2 | 2023-Q1 | 2022-Q4 | 2022-Q3 | 2022-Q2 | 2022-Q1 | 2021-Q4 | 2021-Q3 | 2021-Q2 | 2021-Q1 | 2020-Q4 | 2020-Q3 | 2020-Q2 | 2020-Q1 | 2019-Q4 | 2019-Q3 | 2019-Q2 | 2019-Q1 | 2018-Q4 | 2018-Q3 | 2018-Q2 | 2018-Q1 | 2017-Q4 | 2017-Q3 | 2017-Q2 | 2017-Q1 | 2016-Q4 | 2016-Q3 | 2016-Q2 | 2016-Q1 | 2015-Q4 | 2015-Q3 | 2015-Q2 | 2015-Q1 | 2014-Q4 | 2014-Q3 | 2014-Q2 | 2014-Q1 | 2013-Q4 | 2013-Q3 | 2013-Q2 | 2013-Q1 | 2012-Q4 | 2012-Q3 | 2012-Q2 | 2012-Q1 | 2011-Q4 | 2011-Q3 | 2011-Q2 | 2011-Q1 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Shares |
133 M | 118 M | 110 M | 104 M | 104 M | 102 M | 101 M | 97 M | 95.5 M | 93 M | 88.6 M | 88.2 M | 87.8 M | 87.1 M | 76 M | 75.8 M | 74.8 M | 74.5 M | 73.7 M | 68.2 M | 67.2 M | 61.3 M | 58.8 M | 53.4 M | 50.5 M | 49.4 M | 48.6 M | 45.8 M | 45.2 M | 44.2 M | 43.2 M | 42.8 M | 42 M | 39.2 M | 35.2 M | 34.9 M | 34.7 M | 34.5 M | 34.3 M | 19.1 M | 676 K | 548 K | 294 K | 1.28 M | 1.28 M | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
Net Income |
-107 M | -96.2 M | -101 M | -101 M | -114 M | - | -136 M | -147 M | -107 M | - | -122 M | -124 M | -103 M | - | -113 M | -101 M | -147 M | - | -71.6 M | -68.8 M | -46.2 M | -42.2 M | -27.8 M | -32.4 M | -31.8 M | -28.3 M | -23.6 M | -25.7 M | -21.9 M | -19.1 M | -22.7 M | -22.2 M | -21.4 M | -24 M | -15.4 M | -15.6 M | -12.6 M | -10.6 M | -7.48 M | -6.9 M | -6.69 M | -5.24 M | -3.02 M | -3.04 M | -1.09 M | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
Revenue |
7.66 M | 15 M | 13.8 M | 14.2 M | 16.6 M | - | 9.11 M | 6.96 M | 28.9 M | - | 12 M | 13.6 M | 12.6 M | - | 13.3 M | 14 M | 11.3 M | - | 7.2 M | 6.55 M | 6.44 M | 6.6 M | 22.2 M | 16.3 M | 12.9 M | 10.9 M | 10.6 M | 11.1 M | 10.4 M | 7.88 M | 7.41 M | 7.68 M | 7.47 M | 6.67 M | 7.32 M | 5.92 M | 6.22 M | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
Operating Income |
-113 M | -101 M | -111 M | -110 M | -121 M | - | -145 M | -139 M | -114 M | - | -131 M | -132 M | -112 M | - | -106 M | -98.3 M | -144 M | - | -72 M | -69 M | -46.4 M | -42.4 M | -28.1 M | -33 M | -33 M | -29.8 M | -25.3 M | -27.5 M | -23.8 M | -20.7 M | -24.1 M | -23.6 M | -22.4 M | -24.7 M | -15.9 M | -16 M | -12.9 M | -10.8 M | -7.7 M | -6.95 M | -6.69 M | -5.49 M | -3.3 M | -3.42 M | -1.2 M | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
Interest Expense |
6.13 M | 4.3 M | 10.2 M | 8.74 M | 6.48 M | - | 9.06 M | -7.93 M | 6.57 M | - | 8.88 M | 8.65 M | 8.83 M | - | -7.7 M | -2.38 M | -2.63 M | - | 349 K | - | 220 K | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
EBITDA |
-111 M | -98.3 M | -109 M | -107 M | -118 M | - | -142 M | -136 M | -111 M | - | - | - | -110 M | - | -100 M | -98.3 M | -142 M | - | -67 M | -69 M | -44.8 M | -42.4 M | -23.4 M | -29.9 M | -31.5 M | -29.8 M | -21.3 M | -24.8 M | -22.5 M | -20.7 M | -20.9 M | -21.5 M | -21.4 M | -24.7 M | -13.7 M | -14.6 M | -12.3 M | -10.8 M | -7 M | -6.51 M | -6.51 M | -5.49 M | -3.1 M | -3.32 M | -1.16 M | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
General and Administrative Expenses |
37.8 M | 34.8 M | 30.5 M | 27.2 M | 29 M | - | 30.5 M | 31.8 M | 31.1 M | - | 29.4 M | 30.7 M | 27.4 M | - | 22.1 M | 22.1 M | 22.4 M | - | 18.7 M | 16.7 M | 13.6 M | 10.8 M | 10.6 M | 11.5 M | 11.3 M | 8.98 M | 8.43 M | 13.1 M | 10.5 M | 8.71 M | 8.27 M | 7.8 M | 7.41 M | 10.2 M | 5.71 M | 6.37 M | 5.73 M | 5.12 M | 4.7 M | 3.73 M | 3.25 M | 2.81 M | 1.53 M | 2.83 M | 1.11 M | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
All numbers in USD currency
The income statement is one of the three key financial reports of a company Intellia Therapeutics (alongside the balance sheet and the cash flow statement). It shows how the company makes money and what its expenses are:
- How much revenue the company earned
- How much it spent on production, personnel, marketing, taxes, etc.
- What profit remained in the end
Analyzing the income statement helps an investor understand whether the business generates stable and growing profits, how effectively the company controls its expenses, and whether it is capable of generating income in the future. Additionally, this analysis shows how the company copes with crises and economic cycles, and allows assessing the potential for stock price growth and dividend payments.
Features- The income statement may include both recurring and one-time items (for example, profit from the sale of assets). It is necessary to separate core metrics from one-off events for accurate analysis.
- Companies often publish interim reports (e.g., quarterly), which allows for more timely tracking of trends.
- A combined analysis of the income statement with the balance sheet and cash flow statement provides a comprehensive view of the company’s financial health.
USA
Canada
China
France
Germany
Israel
Britain
Russia
Belgium
Cayman-islands
